Family of recently deceased boy Harvey Morrison Sherratt to meet Simon Harris
Simon Harris
will meet the family of Harvey Morrison Sherratt (9) who died in recent weeks following years of suffering due to spina bifida and scoliosis.
.
He had been subject to delays in accessing urgent scoliosis surgery, during which time he
experienced significant pain
and a reduced quality of life. He underwent surgery at the end of last year.
He died on July 29th, although no cause of death has been established, his mother said in a post on X last week.
READ MORE
Harvey's parents Gillian Sherratt and Stephen Morrison, from Clondalkin in Dublin, have been leading a social-media campaign calling for the resignation of Mr Harris following their son's death.
In 2017, when he was minister for health, Mr Harris pledged that no child would wait more than four months for scoliosis surgery by the end of that year. In a post on X, Ms Sherratt called on the Tánaiste to think 'as a parent of young children'.
'While you create memories with your children, I think about how memories are all we have left, and any future memories made will always have a void. While you kiss them goodbye for the day, I think about when I kissed Harvey goodbye for the last time,' her post said.
Mr Morrison said his son was 'unique', but said 'what isn't unique is the way he and other children and people with disabilities are being failed. It is up to us to stop it.'
They have called for a statutory inquiry into the handling of scoliosis in Ireland.
Harvey Morrison Sherratt's parents Stephen Morrison and Gillian Sherratt have called for a statutory inquiry into the handling of scoliosis in Ireland. Photograph: Collins
It emerged last year that Harvey had been removed from
Children's Health Ireland
's (CHI) urgent scoliosis surgery waiting list, without his family being informed. CHI was contacted for comment.
It previously said it could not comment on individual cases but that waiting lists are 'constantly changing, as children and young people have their surgeries and come off the list, new patients are added'.
'Important progress is being made every month,' it said.
A spokesman for Mr Harris said the Tánaiste had spoken to Ms Sherratt, Harvey's mother, on Wednesday and they 'have agreed to meet in the near future'.
'The Tánaiste has also sought, through the Minister for Health, a full multidisciplinary report on the timeline of care provided to Harvey.'
During a visit to Clonmel, Minister for Finance
Paschal Donohoe
said Mr Harris 'did all he could' when he became aware of the needs of the family 'in terms of engaging with the Department of Health and HSE'.
'I am very conscious that we have a family who have lost a loved one, and are grieving at the moment. They have had such a difficult experience and we have to respect that, and to allow them to make the points that they believe are important,' he said.
'There are still families who need more support, there is still more progress that we need to make.'
Sinn Féin
health spokesman
David Cullinane
said the 'tragic and avoidable passing of Harvey Morrison Sherratt must bring an end to the neglect of children with significant medical needs'.
'Despite the commitment made in 2017 by Simon Harris that no child would wait longer than four months for scoliosis surgery by the end of that year, as of July there are still 38 children waiting longer than six months just for an appointment date.'
Speaking to RTÉ on Wednesday,
Aontú
leader
Peadar Tóibín
called for Mr Harris to resign over his handling of the case.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
2 hours ago
- Irish Times
Gareth Sheridan: Nutriband ‘will help a lot of people who are dealing with addiction and people who are dealing with pain'
Nutriband is a pharmaceutical company that was founded in Dublin in 2012 before relocating to Florida in 2016. Gareth Sheridan, who recently announced his intention to run for president and has stepped aside for three months as chief executive, is its founder. The company's lead product is Aversa, which it describes as 'abuse-deterrent transdermal technology', which incorporates aversive agents to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, specifically opioids. Its first application is its abuse-deterrent fentanyl transdermal patch, which it is developing to provide clinicians and patients with extended-release chronic pain relief. It is awaiting regulatory clearance for this product in the US. The company has operations in Florida, Georgia, and North Carolina, and recently began its expansion back to Dublin. READ MORE What lightbulb moment prompted you to start-up in business? It was originally a thesis idea. I had noticed a patch that my dad wears and began wondering what other types of medications could be delivered that way that had not been explored yet. The thesis became a business plan, and Nutriband was registered in 2012. Describe your business model and what makes your business unique. We structured the company in a unique way, using capital markets and a public listing approach. We listed on the OTC Markets in 2016 and started using stock to purchase companies and technologies in place of cash. This helped us to avoid raising expensive early capital and retain a major equity stake in the company today, even after an eventual qualification to list on the Nasdaq (in New York) in 2010. We also do not develop new drug applications. We take existing generic medications and use our technologies to improve upon those and relaunch them as a branded product again. What is your greatest business achievement to date? Growing the company to a level where we qualified to list on the Nasdaq Stock Exchange and getting to ring the opening bell. What was your back-to-the-wall moment and how did you overcome it? We almost got sued by the SEC (The US Securities and Exchange Commission) for an accidental erroneous disclosure in one of our filings while on the OTC markets. At first, we thought it could be explained. However, it grew to the point where they were doubling down. We hired an excellent attorney with SEC experience and eventually settled the issue in a cease-and-desist, no-admit, no-deny agreement. This led to our back-to-the-wall moment, where, while running on fumes financially, we received a rejection from Nasdaq in our first application. After a couple of days of self-pity, we got back to work, raised some working capital with existing shareholders, and grew the company's equity by $7.5 million (€6.4 million) over the course of the next year. We reapplied to list again successfully. What moment would you cite as a turning point for the company? Credibility provided by our Nasdaq listing and subsequent partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery), where Kindeva supplied their generic approved fentanyl patch for us to add our technology to. What were the best and the worst pieces of advice you received when starting out? The worst advice was that banks and institutions have your company's best interests at heart. I firmly believe that today, Wall Street is built on companies failing, not succeeding. Describe your growth funding path. We were reluctant to raise expensive capital early on and instead listed the company to use stock as an acquisition currency to grow. Our gamble on this paid off, and although we raised modest cash along the way, we were able to build Nutriband without any significant seed or angel rounds. We reached a market capitalisation of $120 million (its market value currently is about $75 million), and we have been able to maintain stable and steady control as a result of the minimal capital rounds. We turn down anywhere from $5 million to $15 million on a weekly basis from funds and institutions because we do not need it. We are not in the business of raising money, and having as little dilution as possible is a core focus for us as a company. How will your market look in three years and where would you like your business to be? For our first product, we are expected to reach annual revenues of $200 million. Our second product is independently estimated to have upwards of $135 million in yearly revenue. We are targeting the billion dollar club before the end of 2027. What are your annual revenues and profits? We are not yet profitable, as is typical with clinical development-stage companies. However, we also contract manufacture sports tapes and products for brands such as Reebok and KT Tape. Our target revenue from this source for the financial year to the end of January 2026 is $3 million * . This goes towards operational costs and reduces our clinical burn. Why have you decided to seek a nomination for the presidency? It's never been a more important or relevant time in our history for a young president, particularly with the average age just under 40. I would be hoping that having a younger president would help narrow the division we're seeing in the country at the moment and that we can work together to tackle the issues, particularly the housing crisis. The younger generation aren't feeling very enthusiastic that their voices are being heard. What impact will this move have on your business? The company is in very safe hands and the biggest asset at the company is the team. We've got a very definite plan and timeline between now and Christmas on what needs to be achieved. Whether I'm in there or not that timeline needs to be adhered to. The company is motoring along fine. Stepping aside is not something that I think will fundamentally affect the opportunity for the company. What happens if you win? There are mechanisms where I can put the shares into a trust. I would be very proud that it was a company that I started and be very keen to still follow the journey, just not as CEO. Nutriband as a whole is going to do a lot of will help a lot of people who are dealing with addiction and people who are dealing with pain. *An earlier version of this article stated a higher target figure for contract manufacturing, which has since been revised by the company.
Irish Times
3 hours ago
- Irish Times
HSE accused of ‘abandoning rural mothers' at protest over Portiuncula maternity services
The HSE was accused of abandoning mothers in rural areas during a protest prompted by concerns over the future of maternity services at Portiuncula University Hospital in Co Galway . About 2,000 people from western and midland counties marched through Ballinasloe on Saturday to chants of 'Care Can't Wait – Reinstate". The demonstration was organised by the Portiuncula Maternity Alliance (PMA), which was established after the HSE decided that expectant mothers with high-risk pregnancies would have their antenatal care moved from Portiuncula to other locations. The decision was taken on foot of a report published last month that summarised five reviews of care provided to women and their babies at Portiuncula and found there were 'significant clinical risks' at the maternity unit. READ MORE The HSE has said it was committed to implementing the 34 recommendations contained in the reviews and had established an implementation team to do this. Protesters carried county flags and placards, one of which read 'No births on the M6!'. Among those participating were nuns from the Franciscan Missionaries of the Divine Motherhood, the order that established the hospital in 1943. Cllr Evelyn Francis Parsons, a GP and Independent member of Galway County Council , told protesters it was wonderful to see such a turnout and that 'together we will not let [the hospital] be downgraded'. 'This hospital and especially its maternity unit is not just bricks and mortar, it has been part of our families, our community for many, many years,' she said. 'Behind every statistic, behind every policy decision, there are real people, mothers, babies, families and staff.' She said mothers' voices have not been heard much in the debate about Portiuncula and she shared some experiences of women cared for there in the past. Ms Parsons cited the case of Mary O'Malley, whose child experienced hypoxic-ischemic encephalopathy, a brain injury caused by a lack of oxygen and blood flow to babies. 'Her care was reviewed. These are her words: 'Forcing a high-risk pregnant woman to travel is not a safety plan. It's a terrifying gamble with our lives, with our babies lives, on the road. We were promised a safe modern service. Instead of delivering that promise, the HSE is abandoning rural mothers, and forcing us to bear the risk of its own strategic failures'.' Kevin Connolly, a retired paediatrician who worked at Portiuncula from 1978 to 2010, said he was very proud to have worked at the hospital. 'I am very concerned that the right thing is not being done, the wrong thing has been imposed on us,' he said. 'What has been imposed on us is not safe, is reducing capacity and taking away resources. It is patently the wrong thing to do and it must stop. We have to win.' Ms Parsons said that 'when services are downgraded they rarely come back', noting the experiences of Nenagh and Roscommon, where accident and emergency departments were closed years ago. 'But I also want you to look at Portlaoise, they fought and they saved their maternity unit. And so can we,' she added. 'We demand proper staffing, proper resourcing and proper respect for our healthcare workers, our nurses, midwives, doctors and all the other staff. 'This is about mothers, the guardians of our future, it's about our babies, our families. It's about equality, about rural families. They deserve the same level of care as families in Dublin, Galway or anywhere else in Ireland.'
Irish Times
14 hours ago
- Irish Times
From goats cheese to hummus - why there has been so many listeria recalls
News last month that a person had died with a rare bacterial infection called listeriosis sparked concern among the public. The Food Safety Authority of Ireland (FSAI) described the outbreak of listeriosis, which is caused by the bacteria listeria monocytogenes, as 'extensive', with nine confirmed cases linked to it by the end of July. The outbreak resulted in a 'voluntary, precautionary recall' of 141 ready-meals produced by Ballymaguire Foods . But in the weeks since, products other than ready-meals have been recalled in relation to listeria. READ MORE Over the past three weeks, there have been recalls for various types of goats cheese, potted coriander , hummus, mixed leaves and spinach , and chicken basil pesto pasta. The publicity around the bacteria understandably shook people's confidence in the safety of food. In a bid to reassure consumers, the FSAI issued a statement clarifying that the subsequent recalls were not related to the outbreak in ready-meals and that it carries out inspections of food production facilities. Serious infection with listeriosis is 'very rare', the authority said, with an average of between 14 and 22 cases in Ireland annually. [ What is listeriosis and its symptoms? Opens in new window ] But why are we hearing so much about it? Cormac Gahan, principal investigator at research centre APC Microbiome Ireland, and a professor in University College Cork's schools of microbiology and pharmacy, said listeria was 'ubiquitous' and often found in the environment, including in soil and plant matter. 'It's the prevalence in the environment that's the main concern. So keeping it out of the food chain is a big concern. There can be unintended consequences when processes go awry,' he said. The bacteria is also 'unusual', he said, in that it grows very slowly when refrigerated. 'So you need to use really good hygiene practices to keep it out of the food chain'. But what is driving the increase in food recalls? There is 'no magic answer', according to Prof Séamus Fanning, professor of food safety at University College Dublin (UCD), but there are a number of factors at play. 'We are able to detect it more often because we have an improved surveillance system. That's down to the technological development over the past 20 or 30 years. Now, our toolbox is much better and we have much more accurate ways of identifying it,' he said. It is a 'tricky organism' to deal with, he said, due to the way in which it 'genetically adapts'. 'So you find it in soil and water. It can then move into a situation where it contaminates a food-processing facility. And then there can be cross-contamination,' he explained. 'It can be difficult to get rid of it in a factory. If it raises its head, and there are positive [tests] then you must do a major, major clean.' Prof Gahan believes another reason there has been an increase in recalls is due to the recent publicity around the listeriosis outbreak relating to ready-meals. That, he said, is likely to have resulted in food manufacturers increasing their testing due to public discourse around the topic. 'The more testing there is, the more recalls there will be,' he added. Despite all the recent publicity, the two professors believe consumers can still be confident their food is safe. They highlight the at-risk groups – such as older people , the immunocompromised or those who are pregnant – but said for most people it causes only flu-like symptoms that will resolve by itself. 'We also have strong regulatory and food safety systems. The food recalls could be viewed as a risk-reduction measure,' Prof Fanning said. Prof Gahan agrees: 'Ireland's rates of infection are relatively low. We have good procedures in place.'
